15 results on '"Lawrence D, Harris"'
Search Results
2. Uncoupling Molecular Testing for SARS-CoV-2 From International Supply Chains
- Author
-
Jo-Ann L. Stanton, Rory O'Brien, Richard J. Hall, Anastasia Chernyavtseva, Hye Jeong Ha, Lauren Jelley, Peter D. Mace, Alexander Klenov, Jackson M. Treece, John D. Fraser, Fiona Clow, Lewis Clarke, Yongdong Su, Harikrishnan M. Kurup, Vyacheslav V. Filichev, William Rolleston, Lee Law, Phillip M. Rendle, Lawrence D. Harris, James M. Wood, Thomas W. Scully, James E. Ussher, Jenny Grant, Timothy A. Hore, Tim V. Moser, Rhodri Harfoot, Blair Lawley, Miguel E. Quiñones-Mateu, Patrick Collins, and Richard Blaikie
- Subjects
COVID-19 ,RT-qPCR ,molecular reagents ,supply chain ,HomeBrew ,Public aspects of medicine ,RA1-1270 - Abstract
The rapid global rise of COVID-19 from late 2019 caught major manufacturers of RT-qPCR reagents by surprise and threw into sharp focus the heavy reliance of molecular diagnostic providers on a handful of reagent suppliers. In addition, lockdown and transport bans, necessarily imposed to contain disease spread, put pressure on global supply lines with freight volumes severely restricted. These issues were acutely felt in New Zealand, an island nation located at the end of most supply lines. This led New Zealand scientists to pose the hypothetical question: in a doomsday scenario where access to COVID-19 RT-qPCR reagents became unavailable, would New Zealand possess the expertise and infrastructure to make its own reagents onshore? In this work we describe a review of New Zealand's COVID-19 test requirements, bring together local experts and resources to make all reagents for the RT-qPCR process, and create a COVID-19 diagnostic assay referred to as HomeBrew (HB) RT-qPCR from onshore synthesized components. This one-step RT-qPCR assay was evaluated using clinical samples and shown to be comparable to a commercial COVID-19 assay. Through this work we show New Zealand has both the expertise and, with sufficient lead time and forward planning, infrastructure capacity to meet reagent supply challenges if they were ever to emerge.
- Published
- 2022
- Full Text
- View/download PDF
3. 3α,7-Dihydroxy-14(13→12)abeo-5β,12α(H),13β(H)-cholan-24-oic Acids Display Neuroprotective Properties in Common Forms of Parkinson’s Disease
- Author
-
Andreas Luxenburger, Hannah Clemmens, Christopher Hastings, Lawrence D. Harris, Elizabeth M. Ure, Scott A. Cameron, Jan Aasly, Oliver Bandmann, Alex Weymouth-Wilson, Richard H. Furneaux, and Heather Mortiboys
- Subjects
bile acids ,C-nor-D-homo bile acids ,rearrangement ,drug discovery ,neurodegenerative diseases ,Parkinson’s Disease ,Microbiology ,QR1-502 - Abstract
Parkinson’s Disease is the most common neurodegenerative movement disorder globally, with prevalence increasing. There is an urgent need for new therapeutics which are disease-modifying rather than symptomatic. Mitochondrial dysfunction is a well-documented mechanism in both sporadic and familial Parkinson’s Disease. Furthermore, ursodeoxycholic acid (UDCA) has been identified as a bile acid which leads to increased mitochondrial function in multiple in vitro and in vivo models of Parkinson’s Disease. Here, we describe the synthesis of novel C-nor-D-homo bile acid derivatives and the 12-hydroxy-methylated derivative of lagocholic acid (7) and their biological evaluation in fibroblasts from patients with either sporadic or LRRK2 mutant Parkinson’s Disease. These compounds boost mitochondrial function to a similar level or above that of UDCA in many assays; notable, however, is their ability to boost mitochondrial function to a higher level and at lower concentrations than UDCA specifically in the fibroblasts from LRRK2 patients. Our study indicates that novel bile acid chemistry could lead to the development of more efficacious bile acids which increase mitochondrial function and ultimately cellular health at lower concentrations proving attractive potential novel therapeutics for Parkinson’s Disease.
- Published
- 2022
- Full Text
- View/download PDF
4. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective
- Author
-
Mona Seifert, Subhas C Bera, Pauline van Nies, Robert N Kirchdoerfer, Ashleigh Shannon, Thi-Tuyet-Nhung Le, Xiangzhi Meng, Hongjie Xia, James M Wood, Lawrence D Harris, Flavia S Papini, Jamie J Arnold, Steven Almo, Tyler L Grove, Pei-Yong Shi, Yan Xiang, Bruno Canard, Martin Depken, Craig E Cameron, and David Dulin
- Subjects
SARS-CoV-2 ,antiviral drugs ,mechanism of action ,Remdesivir ,high throughput magnetic tweezers ,single molecule biophysics ,Medicine ,Science ,Biology (General) ,QH301-705.5 - Abstract
The absence of ‘shovel-ready’ anti-coronavirus drugs during vaccine development has exceedingly worsened the SARS-CoV-2 pandemic. Furthermore, new vaccine-resistant variants and coronavirus outbreaks may occur in the near future, and we must be ready to face this possibility. However, efficient antiviral drugs are still lacking to this day, due to our poor understanding of the mode of incorporation and mechanism of action of nucleotides analogs that target the coronavirus polymerase to impair its essential activity. Here, we characterize the impact of remdesivir (RDV, the only FDA-approved anti-coronavirus drug) and other nucleotide analogs (NAs) on RNA synthesis by the coronavirus polymerase using a high-throughput, single-molecule, magnetic-tweezers platform. We reveal that the location of the modification in the ribose or in the base dictates the catalytic pathway(s) used for its incorporation. We show that RDV incorporation does not terminate viral RNA synthesis, but leads the polymerase into backtrack as far as 30 nt, which may appear as termination in traditional ensemble assays. SARS-CoV-2 is able to evade the endogenously synthesized product of the viperin antiviral protein, ddhCTP, though the polymerase incorporates this NA well. This experimental paradigm is essential to the discovery and development of therapeutics targeting viral polymerases.
- Published
- 2021
- Full Text
- View/download PDF
5. An Isomer of Galidesivir That Potently Inhibits Influenza Viruses and Members of the Bunyavirales Order
- Author
-
Kevin J. Sparrow, Rinu Shrestha, James M. Wood, Keith Clinch, Brett L. Hurst, Hong Wang, Brian B. Gowen, Justin G. Julander, E. Bart Tarbet, Alice M. McSweeney, Vernon K. Ward, Gary B. Evans, and Lawrence. D. Harris
- Subjects
Organic Chemistry ,Drug Discovery ,Biochemistry - Published
- 2023
6. Synthesis of Novel C/D Ring Modified Bile Acids
- Author
-
Roselis A. Landaeta Aponte, Andreas Luxenburger, Scott A. Cameron, Alex Weymouth-Wilson, Richard H. Furneaux, Lawrence D. Harris, and Benjamin J. Compton
- Subjects
bile acid ,zinc carbenoids ,cyclopropane ,rearrangement ,drug discovery ,Organic chemistry ,QD241-441 - Abstract
Bile acid receptors have been identified as important targets for the development of new therapeutics to treat various metabolic and inflammatory diseases. The synthesis of new bile acid analogues can help elucidate structure–activity relationships and define compounds that activate these receptors selectively. Towards this, access to large quantities of a chenodeoxycholic acid derivative bearing a C-12 methyl and a C-13 to C-14 double bond provided an interesting scaffold to investigate the chemical manipulation of the C/D ring junction in bile acids. The reactivity of this alkene substrate with various zinc carbenoid species showed that those generated using the Furukawa methodology achieved selective α-cyclopropanation, whereas those generated using the Shi methodology reacted in an unexpected manner giving rise to a rearranged skeleton whereby the C ring has undergone contraction to form a novel spiro–furan ring system. Further derivatization of the cyclopropanated steroid included O-7 oxidation and epimerization to afford new bile acid derivatives for biological evaluation.
- Published
- 2022
- Full Text
- View/download PDF
7. SARS-CoV-2 Infection Biomarkers Reveal an Extended RSAD2 Dependant Metabolic Pathway
- Author
-
Samuele Sala, Philipp Nitschke, Reika Masuda, Nicola Gray, Nathan Lawler, James M. Wood, Georgy Berezhnoy, Alejandro Bolaños, Berin A. Boughton, Caterina Lonati, Titus Rössler, Yogesh Singh, Ian D. Wilson, Samantha Lodge, Aude-Claire Morillon, Ruey Leng Loo, Drew Hall, Luke Whiley, Gary B. Evans, Tyler L. Grove, Steven C. Almo, Lawrence D. Harris, Elaine Holmes, Uta Merle, Christoph Trautwein, Jeremy K. Nicholson, and Julien Wist
- Abstract
We present compelling evidence for the existence of an evolutionary adaptive response to viral agents such as SARS-CoV-2, that results in the humanin vivobiosynthesis of a family of compounds with potential antiviral activity. Using nuclear magnetic resonance (NMR) spectroscopy, we detected a characteristic spin-system motif indicative of the presence of an extended panel of urinary and serum metabolites during the acute viral phase. The structure of eight of nucleoside analogues was elucidated (six of which have not previously been reported in human urine), and subsequently confirmed by total-synthesis and matrix spiking. The molecular structures of the nucleoside analogues and their correlation with an array of serum cytokines, including IFN-α2, IFN-γ and IL-10, suggest an association with the viperin enzyme contributing to an endogenous innate immune defense mechanism against viral infection.
- Published
- 2023
8. Synthesis of 12β-methyl-18-nor-avicholic acid analogues as potential TGR5 agonists
- Author
-
Elizabeth M. Ure, Lawrence D. Harris, Scott A. Cameron, Alex Weymouth-Wilson, Richard H. Furneaux, Janet L. Pitman, Simon. F. Hinkley, and Andreas Luxenburger
- Subjects
Organic Chemistry ,Physical and Theoretical Chemistry ,Biochemistry - Abstract
A series of 12β-methyl-18-nor-avicholic acid analogues was prepared and evaluated for activity at TGR5 and FXR. Compounds 46 and 53 emerged as low-micromolar TGR5 agonists, providing potential new templates for further development.
- Published
- 2022
9. Discovery of AL-GDa62 as a Potential Synthetic Lethal Lead for the Treatment of Gastric Cancer
- Author
-
Andreas Luxenburger, Nicola Bougen-Zhukov, Michael G. Fraser, Henry Beetham, Lawrence D. Harris, Dorian Schmidt, Scott A. Cameron, Parry J. Guilford, and Gary B. Evans
- Subjects
Antigens, CD ,Stomach Neoplasms ,Cell Line, Tumor ,Mutation ,Drug Discovery ,Humans ,Molecular Medicine ,Antineoplastic Agents ,Apoptosis ,Cadherins - Abstract
Diffuse gastric cancer and lobular breast cancer are aggressive malignancies that are frequently associated with inactivating mutations in the tumor suppressor gene
- Published
- 2021
10. 3α,7-Dihydroxy-14(13→12)abeo-5β,12α(H),13β(H)-cholan-24-oic Acids Display Neuroprotective Properties in Common Forms of Parkinson’s Disease
- Author
-
Mortiboys, Andreas Luxenburger, Hannah Clemmens, Christopher Hastings, Lawrence D. Harris, Elizabeth M. Ure, Scott A. Cameron, Jan Aasly, Oliver Bandmann, Alex Weymouth-Wilson, Richard H. Furneaux, and Heather
- Subjects
bile acids ,C-nor-D-homo bile acids ,rearrangement ,drug discovery ,neurodegenerative diseases ,Parkinson’s Disease ,UDCA ,LRRK2 - Abstract
Parkinson’s Disease is the most common neurodegenerative movement disorder globally, with prevalence increasing. There is an urgent need for new therapeutics which are disease-modifying rather than symptomatic. Mitochondrial dysfunction is a well-documented mechanism in both sporadic and familial Parkinson’s Disease. Furthermore, ursodeoxycholic acid (UDCA) has been identified as a bile acid which leads to increased mitochondrial function in multiple in vitro and in vivo models of Parkinson’s Disease. Here, we describe the synthesis of novel C-nor-D-homo bile acid derivatives and the 12-hydroxy-methylated derivative of lagocholic acid (7) and their biological evaluation in fibroblasts from patients with either sporadic or LRRK2 mutant Parkinson’s Disease. These compounds boost mitochondrial function to a similar level or above that of UDCA in many assays; notable, however, is their ability to boost mitochondrial function to a higher level and at lower concentrations than UDCA specifically in the fibroblasts from LRRK2 patients. Our study indicates that novel bile acid chemistry could lead to the development of more efficacious bile acids which increase mitochondrial function and ultimately cellular health at lower concentrations proving attractive potential novel therapeutics for Parkinson’s Disease.
- Published
- 2022
- Full Text
- View/download PDF
11. Inhibition of the DENV2 and ZIKV RNA polymerases by Galidesivir triphosphate measured using a continuous fluorescence assay
- Author
-
Sandesh Deshpande, Wenjuan Huo, Rinu Shrestha, Kevin Sparrow, Gary B. Evans, Lawrence D. Harris, Richard L. Kingston, and Esther M. M. Bulloch
- Abstract
Millions of people are infected by the Dengue and Zika viruses each year, which can result in serious illness, permanent disability or death. There are currently no FDA-approved antivirals for treating infection by these viruses. Galidesivir is an adenosine nucleoside analog which can attenuate flavivirus replication in cell-based and animal models of infection. Galidesivir is converted to the triphosphorylated form by host kinases, and subsequently incorporated into viral RNA by viral RNA-dependent RNA polymerases, leading to the termination of RNA synthesis via an unknown mechanism. Here we report the directin vitrotesting of the effects of Galidesivir triphosphate on RNA synthesis by the polymerases of Dengue-2 and Zika virus. Galidesivir triphosphate was chemically synthesized and inhibition of RNA synthesis followed using a continuous fluorescence-based assay. Galidesivir triphosphate was equipotent against the polymerase activity of Dengue-2 and Zika, with IC50values of 42 ± 12 μM and 47 ± 5 μM, respectively. This modest potencyin vitrois consistent with results previously obtained in cell-based antiviral assays and suggests that the binding affinity for Galidesivir triphosphate is similar to the natural ATP substrate that it closely mimics. The inhibition assay we have developed will allow the rapid screening of Galidesivir and related compounds against other flavivirus polymerases, and the availability of Galidesivir triphosphate will allow detailed analysis of its mechanism of action.HighlightsGalidesivir triphosphate was chemically synthesized.A continuous assay detecting double-stranded RNA formation was optimized for polymerase inhibition studies.Galidesivir triphosphate has moderate potency against DENV2 and ZIKA polymerase activity.The availability of Galidesivir triphosphate will facilitate study of its mechanism of action.
- Published
- 2022
12. Synthesis of a putative ddhCTP metabolite ddhC-homocysteine
- Author
-
James M. Wood, Joshua N. Buckler, Steven C. Almo, Gary B. Evans, Tyler L. Grove, and Lawrence D. Harris
- Subjects
Organic Chemistry ,Drug Discovery ,Biochemistry - Published
- 2023
13. Mechanism-Based Inactivation of
- Author
-
Drake M, Mellott, Dan, Torres, Inna V, Krieger, Scott A, Cameron, Zahra, Moghadamchargari, Arthur, Laganowsky, James C, Sacchettini, Thomas D, Meek, and Lawrence D, Harris
- Subjects
Kinetics ,Models, Chemical ,Glyoxylates ,Succinates ,Mycobacterium tuberculosis ,Enzyme Inhibitors ,Propionates ,Nitro Compounds ,Isocitrate Lyase ,Protein Binding - Abstract
The isocitrate lyase paralogs of
- Published
- 2021
14. Aminofutalosine Deaminase in the Menaquinone Pathway of
- Author
-
Mu, Feng, Rajesh K, Harijan, Lawrence D, Harris, Peter C, Tyler, Richard F G, Fröhlich, Morais, Brown, and Vern L, Schramm
- Subjects
Models, Molecular ,Thionucleosides ,Deoxyadenosines ,Helicobacter pylori ,Purine-Nucleoside Phosphorylase ,Catalytic Domain ,Nucleosides ,Vitamin K 2 ,Crystallography, X-Ray ,N-Glycosyl Hydrolases ,Article ,Substrate Specificity - Abstract
Helicobacter pylori is a Gram-negative bacterium that is responsible for gastric and duodenal ulcers. H. pylori uses the unusual mqn pathway with aminofutalosine (AFL) as an intermediate for menaquinone biosynthesis. Previous reports indicate that hydrolysis of AFL by 5′-methylthioadenosine nucleosidase (HpMTAN) is the direct path for producing downstream metabolites in the mqn pathway. However, genomic analysis indicates jhp0252 is a candidate for encoding AFL deaminase (AFLDA), an activity for deaminating aminofutolasine. The product, futalosine, is not a known substrate for bacterial MTANs. Recombinant jhp0252 was expressed and characterized as an AFL deaminase (HpAFLDA). Its catalytic specificity includes AFL, 5′-methylthioadenosine, 5′-deoxyadenosine, adenosine, and S-adenosylhomocysteine. The k(cat)/K(m) value for AFL is 6.8 × 10(4) M(−1) s(−1), 26-fold greater than that for adenosine. 5′-Methylthiocoformycin (MTCF) is a slow-onset inhibitor for HpAFLDA and demonstrated inhibitory effects on H. pylori growth. Supplementation with futalosine partially restored H. pylori growth under MTCF treatment, suggesting AFL deamination is significant for cell growth. The crystal structures of apo-HpAFLDA and with MTCF at the catalytic sites show a catalytic site Zn(2+) or Fe(2+) as the water-activating group. With bound MTCF, the metal ion is 2.0 Å from the sp(3) hydroxyl group of the transition state analogue. Metabolomics analysis revealed that HpAFLDA has intracellular activity and is inhibited by MTCF. The mqn pathway in H. pylori bifurcates at aminofutalosine with HpMTAN producing adenine and depurinated futalosine and HpAFLDA producing futalosine. Inhibition of cellular HpMTAN or HpAFLDA decreased the cellular content of menaquinone-6, supporting roles for both enzymes in the pathway.
- Published
- 2021
15. Viperin triggers ribosome collision-dependent translation inhibition to restrict viral replication
- Author
-
Jack Chun-Chieh Hsu, Maudry Laurent-Rolle, Joanna B. Pawlak, Hongjie Xia, Amit Kunte, Jia Shee Hee, Jaechul Lim, Lawrence D. Harris, James M. Wood, Gary B. Evans, Pei-Yong Shi, Tyler L. Grove, Steven C. Almo, and Peter Cresswell
- Subjects
Oxidoreductases Acting on CH-CH Group Donors ,S-Adenosylmethionine ,Proteins ,Cell Biology ,Virus Replication ,Antiviral Agents ,Ribosomes ,Molecular Biology ,Immunity, Innate ,Article - Abstract
Innate immune responses induce hundreds of interferon-stimulated genes (ISGs). Viperin, a member of the radical S-adenosyl methionine (SAM) superfamily of enzymes, is the product of one such ISG that restricts the replication of a broad spectrum of viruses. Here, we report a previously unknown antiviral mechanism in which viperin activates a ribosome collision-dependent pathway that inhibits both cellular and viral RNA translation. We found that the radical SAM activity of viperin is required for translation inhibition and that this is mediated by viperin's enzymatic product, 3'-deoxy-3',4'-didehydro-CTP (ddhCTP). Viperin triggers ribosome collisions and activates the MAPKKK ZAK pathway that in turn activates the GCN2 arm of the integrated stress response pathway to inhibit translation. The study illustrates the importance of translational repression in the antiviral response and identifies viperin as a translation regulator in innate immunity.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.